Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Japanese Pharmaceuticals and Medical Devices
Agency (PMDA) has approved MARIZEV (omarigliptin) 25 mg and
12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the
treatment of adults with type 2 diabetes. Japan is the first country to
have approved omarigliptin.
Language:
English
Contact:
Media Contacts:Pam Eisele, 267-305-3558orMichael Close, 310-617-1067orKristen Drake, 908-236-4223orInvestor Contacts:Justin Holko, 908-740-1879orTeri Loxam, 908-740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more